However, in some patients, it has shortcomings such as low response rates, a single target, significant side effects, and easy recurrence [25].On the one hand, the therapeutic effects of ICIs depend on the basic function of the body’s anti-tumor immune response [26], and tumor ICIs represented by PD-1/PD-L1 have limited response to "cold" tumor patients without immune cell infiltration in tumor tissues. This evidence concerns the gene PDCD1 and neoplasm.